Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab

Therapeutic Advances in Hematology
Josep-Maria RiberaJordi Ribera

Abstract

Bispecific T-cell engaging antibodies are constructs engineered to bind to two different antigens, one to a tumor-specific target and the other to CD3-positive T cells or natural killer (NK) cells. Blinatumomab engages CD19 and CD3, performing effective serial lysis. The clinical development program in acute lymphoblastic leukemia (ALL) includes clinical trials in relapsed or refractory (R/R) patients and in B-cell precursor (BCP) ALL patients with measurable residual disease. Several trials are currently being conducted in de novo BCP-ALL, either in induction, consolidation, or before or after hematopoietic stem cell transplant. Combination with other targeted therapies or with other immunotherapeutic approaches are also underway. Several strategies are aimed to optimize the use of blinatumomab either by overcoming the mechanisms of resistance (e.g. inhibition of PD-1/PD-L1) or by improvements in the route of application, among others.

References

Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Jul 6, 2007·Leukemia·E TavernierUNKNOWN Australasian Leukaemia and Lymphoma Group
Feb 11, 2010·Haematologica·Albert OriolUNKNOWN Programa Español de Tratamiento en Hematologia Group
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Mar 4, 2014·British Journal of Haematology·Anjali S AdvaniFrederick R Appelbaum
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Max S ToppRalf C Bargou
May 23, 2015·Blood·Elias JabbourHagop Kantarjian
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Sep 15, 2016·The New England Journal of Medicine·Sébastien MauryUNKNOWN for GRAALL
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arend von StackelbergLia Gore
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Jul 13, 2018·Therapeutic Advances in Vaccines and Immunotherapy·Eva DahlénPer Norlén
Feb 17, 2019·Clinical Pharmacology and Therapeutics·Johannes DuellSaar Gill

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01209286
NCT01466179
NCT01471782
NCT02187354
NCT02000427
NCT00560794
NCT01207388
NCT02013167
NCT03263572
NCT02744768

Software Mentioned

ELIANA
BiTE
TOWER
RIALTO

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.